Sogen Data · Datasets · 数据专题

卵巢癌复发轴数据集锦

单细胞 · 空转 · bulk 转录组

本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。

人源单细胞

Human · Single-cell

  1. 01 GSE158722 对9名高分级卵巢癌患者的恶性液体样本进行单细胞RNA测序,包含治疗前8例、治疗中不同时间点24例及治疗后7例,采用iCell8和10X技术检测转录组差异。 人源 · 39 例 · GPL16791;24676 · 2021/02/09

    设计对9名高分级卵巢癌患者的恶性液体样本进行单细胞RNA测序,包含治疗前8例、治疗中不同时间点24例及治疗后7例,采用iCell8和10X技术检测转录组差异。

    摘要24 malignant fluid samples were collected from 9 high-grade ovarian cancer patients at various time points over the course of chemotherapy. Additionally, an independent cohort of 8 malignant fluid samples were collected from pre-treatment patients and 7 samples from post-treatment patients. Single-cell RNA sequencing (scRNA-seq) was performed using 10X or iCell8 technologies.

  2. 02 GSE241221 对卵巢癌复发的单细胞进行单细胞 TCR 测序,分组为接受化疗处理与未接受化疗处理,比较两组间细胞特征差异。 人源 · 11 例 · GPL16791 · 2024/03/13

    设计对卵巢癌复发的单细胞进行单细胞 TCR 测序,分组为接受化疗处理与未接受化疗处理,比较两组间细胞特征差异。

    摘要Using single-cell RNA sequencing, we assessed the systemic impact of chemotherapy on tumor, stromal, and immune cells in the high-grade serous ovarian carcinoma. The results reveal remodeling of the T cell profiles towards a more naïve state and the upregulation of the epithelial-mesenchymal transition signatures in surviving tumor cells. These alterations suggest cellular and molecular targets for the therapeutic development in chemotherapy-resistant ovarian cancer.

  3. 03 GSE318490 本研究对六名晚期高分级浆液性卵巢癌(HGSOC)患者的10个肿瘤样本进行单细胞RNA测序,样本来自卵巢、网膜、腹膜和盆腔复发肿瘤等不同组织,涵盖新辅助化疗前、化疗后及铂敏感复发三个临床阶段。通过分析各阶段肿瘤微环境的转录特征,比较不同治疗阶段下的细胞组成与异质性变化。 人源 · 10 例 · GPL24676 · 2026/03/03

    设计本研究对六名晚期高分级浆液性卵巢癌(HGSOC)患者的10个肿瘤样本进行单细胞RNA测序,样本来自卵巢、网膜、腹膜和盆腔复发肿瘤等不同组织,涵盖新辅助化疗前、化疗后及铂敏感复发三个临床阶段。通过分析各阶段肿瘤微环境的转录特征,比较不同治疗阶段下的细胞组成与异质性变化。

    摘要High-grade serous ovarian cancer (HGSOC) is characterized by pronounced cellular heterogeneity and dynamic changes during treatment and recurrence. In this study, we collected 10 tumor samples from six patients with advanced-stage HGSOC and performed single-cell RNA sequencing (scRNA-seq) to profile the tumor ecosystem across different treatment stages, including pre-neoadjuvant chemotherapy (pre-NACT), post-neoadjuvant chemotherapy (post-NACT), and platinum-sensitive recurrence. Single-cell libraries were prepared using the 10x Genomics platform followed by high-throughput sequencing. This dataset provides a resource for investigating transcriptional heterogeneity and cellular composition changes associated with treatment and recurrence in advanced HGSOC.

  4. 04 GSE130000 对8例卵巢癌样本(包括4例原发肿瘤、2例腹膜转移和2例复发肿瘤)进行单细胞RNA测序,分析不同肿瘤类型单细胞的转录组特征。肿瘤组织经解离处理后按Drop-seq协议进行单细胞测序,未提及混池或重复信息。 人源 · 8 例 · GPL18573 · 2020/08/21

    设计对8例卵巢癌样本(包括4例原发肿瘤、2例腹膜转移和2例复发肿瘤)进行单细胞RNA测序,分析不同肿瘤类型单细胞的转录组特征。肿瘤组织经解离处理后按Drop-seq协议进行单细胞测序,未提及混池或重复信息。

    摘要To understand the recurrence of ovarian cancer, we profiled 13369 single cells from 8 ovarian cancer samples, including 4 primary tumors, 2 peritoneal metastasis and 2 relapse tumors by single cell RNA-seq.

  5. 05 GSE307725 对三名高分级浆液性卵巢癌复发患者的四个单细胞样本进行单细胞RNA测序,获取肿瘤微环境的基因表达谱和细胞类型注释,比较不同样本间的转录组差异。 人源 · 4 例 · GPL24676 · 2025/09/15

    设计对三名高分级浆液性卵巢癌复发患者的四个单细胞样本进行单细胞RNA测序,获取肿瘤微环境的基因表达谱和细胞类型注释,比较不同样本间的转录组差异。

    摘要To characterize the tumor microenvironment (TME) of recurrence-stage high-grade serous ovarian cancer (HGSC) at the single cell level, we performed single-cell RNA sequencing (scRNA-seq) for a total of four samples from three patients. This data set includes scRNA-seq read count data and cell type annotations for each sample.

人源空转

Human · Spatial

  1. 01 GSE263920 对8例高分级浆液性卵巢癌(HGSOC)患者进行空间转录组测序,按60个月复发标准分为复发组(R,n=5)和非复发组(NR,n=3),比较两组肿瘤微环境的空间转录特征差异。 人源 · 8 例 · GPL24676 · 2024/04/18

    设计对8例高分级浆液性卵巢癌(HGSOC)患者进行空间转录组测序,按60个月复发标准分为复发组(R,n=5)和非复发组(NR,n=3),比较两组肿瘤微环境的空间转录特征差异。

    摘要Our study utilized spatial transcriptomics (ST) to interpret the tumor microenvironment to examine spatial characteristics across different sites in eight patients with HGSOC divided into recurrent (R, n = 5) and non-recurrent (NR, n = 3) groups based on a 60-month recurrence criterion. This study identified diagnostic and therapeutic targets for HGSOC, marking a step towards personalized medicine.

人源bulk 转录组

Human · Bulk RNA-seq

  1. 01 GSE208103 对卵巢癌复发患者FFPE组织样本进行基因表达分析,收集来自MITO16/MaNGO-OV2临床试验的196个样本,使用GeneChip WT Pico试剂盒检测,比较不同EGFR状态(M0、M、MM)及Bentink亚型(Angiogenic、nonAngiogenic)的基因表达差异。 人源 · 196 例 · GPL23126 · 2023/04/19

    设计对卵巢癌复发患者FFPE组织样本进行基因表达分析,收集来自MITO16/MaNGO-OV2临床试验的196个样本,使用GeneChip WT Pico试剂盒检测,比较不同EGFR状态(M0、M、MM)及Bentink亚型(Angiogenic、nonAngiogenic)的基因表达差异。

    摘要MITO16/MaNGO-OV2 (NCT01706120) is a multicenter, phase IV, single arm trial for advanced stage IIIB-IV or recurrent, previously untreated, ovarian cancer patients receiving carboplatin, paclitaxel plus bevacizumab for six 3-weekly cycles followed by bevacizumab single agent until progression or unacceptable toxicity up to a maximum of 22 total cycles. The trial that was specifically designed with a translational primary endpoint to explore if selected clinical and biological factors could identify ovarian cancer patients with better prognosis in terms of progression free survival and overall survival after combined first-line treatment with chemotherapy plus Bevacizumab. The translational study, designed together with the clinical trial, the translational study implicated the collection of patients’ tissue (formalin-fixed paraffin-embedded – FFPE) and blood samples. Gene expression profile was among the molecular analyses proposed on FFPE samples.

  2. 02 GSE51088 将卵巢组织样本(n=172)与包含正常、良性、边界性和恶性样本的参考池(n=106)进行比较,通过RNA提取和表达分析检测不同样本类型的基因表达差异。 人源 · 172 例 · GPL7264 · 2013/12/26

    设计将卵巢组织样本(n=172)与包含正常、良性、边界性和恶性样本的参考池(n=106)进行比较,通过RNA提取和表达分析检测不同样本类型的基因表达差异。

    摘要The goal of the study was to identify molecular subgroups that might predict clinical outcomes in serous epithelial ovarian cancer (EOC) patients. A second objective was to identify potential therapeutic targets for serous EOC based on improved understanding of the molecular diversity of the disease. Ovarian tissues and matched peripheral blood samples were prospectively obtained from sequential patients undergoing planned gynecologic surgery at Cedars-Sinai Medical Center between 1989 and 2005. All patients underwent surgery and received adjuvant chemotherapy with a contemporaneous standard-of-care regimen.

  3. 03 GSE211669 对高分级浆液性卵巢癌(HGSC)患者进行转录组分析,比较生存超过10年的长期存活者与短期或中期存活者的肿瘤样本特征。研究对象包括53例原发肿瘤和3例复发肿瘤样本,共56例HGSC患者,同时整合GSE209964的75例样本作为对照。通过bulk RNA测序检测基因表达,分析长期存活者与对照组在基因组特征、免疫细胞标志物及BRCA1突变亚型间的差异。 人源 · 131 例 · GPL11154;24676 · 2022/08/26

    设计对高分级浆液性卵巢癌(HGSC)患者进行转录组分析,比较生存超过10年的长期存活者与短期或中期存活者的肿瘤样本特征。研究对象包括53例原发肿瘤和3例复发肿瘤样本,共56例HGSC患者,同时整合GSE209964的75例样本作为对照。通过bulk RNA测序检测基因表达,分析长期存活者与对照组在基因组特征、免疫细胞标志物及BRCA1突变亚型间的差异。

    摘要Less than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSC) survive more than five years post-diagnosis but those who have an exceptionally long survival could provide new insights into tumor biology and therapeutic approaches. We analyzed 60 patients with advanced-stage, HGSC who survived more than 10 years after diagnosis using whole-genome sequencing, transcriptome, and methylome profiling of their primary tumor samples, comparing this data to 66 short- or moderate-term survivors. Tumors of long-term survivors were more likely to have multiple alterations in genes associated with DNA repair, and more frequent somatic variants resulting in an increased predicted neoantigen load. Patients clustered into survival groups based on genomic and immune cell signatures, including three subsets of patients with BRCA1 alterations with distinctly different outcomes. Specific combinations of germline and somatic gene alterations, tumor cell phenotypes, and differential immune responses appear to contribute to long-term survival in HGSC.

  4. 04 GSE17260 对110例接受初次手术及铂类/紫杉烷类化疗的晚期黏液性卵巢癌患者进行总RNA表达谱分析,通过单变量Cox比例风险分析筛选出88个与无进展生存期相关的基因,再利用岭回归模型结合10折交叉验证优化回归系数。研究比较了该基因表达指数与无进展生存期及总生存期的关联性,发现其在多变量分析中独立预测无进展生存期,且在两个独立外部数据集中验证了其预测能力。 人源 · 110 例 · GPL6480 · 2010/03/22

    设计对110例接受初次手术及铂类/紫杉烷类化疗的晚期黏液性卵巢癌患者进行总RNA表达谱分析,通过单变量Cox比例风险分析筛选出88个与无进展生存期相关的基因,再利用岭回归模型结合10折交叉验证优化回归系数。研究比较了该基因表达指数与无进展生存期及总生存期的关联性,发现其在多变量分析中独立预测无进展生存期,且在两个独立外部数据集中验证了其预测能力。

    摘要To identify and evaluate the prognostic ability of progression-free survival-related profile for advanced-stage ovarian cancer, advanced-stage serous ovarian cancer tissues from 110 patients who received primary surgery and a platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays of more than 40,000 transcripts. We first selected 88 genes by a univariate Cox proportional hazard analysis (p<0.01) and next optimized regression coefficients by ridge regression model using 10-fold cross-validation. The prognostic index was independently associated with PFS time compared to other clinical factors in multivariate analysis [hazard ratio (HR), 3.72; 95% confidence interval (CI), 2.66–5.43; p,0.0001]. In an external dataset, multivariate analysis revealed that this prognostic index was significantly correlated with PFS time (HR, 1.54; 95% CI, 1.20–1.98; p = 0.0008). Furthermore, the correlation between the prognostic index and overall survival time was confirmed in the two independent external datasets (log rank test, p = 0.0010 and 0.0008). In multivariable analysis, our prognostic index was independently associated with progression-free survival times compared to other clinical factors (p<0.001). Furthermore, the prognostic ability of our prognostic index was validated in external, publicly available dataset (n = 87), and was proved in multivariate analysis (p = 0.0032). These results suggest that disease progression or recurrence of advanced-stage serous ovarian cancer can be predicted by gene expression profile. The prognostic ability of our index based on the 88-gene expression profile in ridge regression Cox hazard model was shown to be independent of other clinical factors in predicting cancer prognosis across two distinct datasets. Further study will be necessary to improve predictive accuracy of the prognostic index toward clinical application for evaluation of the risk of recurrence in patients with advanced-stage serous ovarian cancer.

  5. 05 GSE8841 对83例早期卵巢癌样本进行基因表达分析,其中68例为I期癌变样本,15例为边界性病变样本。所有样本均为人类来源,采用微阵列技术检测总RNA表达,未涉及特定处理条件或分组混池方式,主要比较不同组织类型与疾病状态下的基因表达差异。 人源 · 83 例 · GPL5689 · 2007/08/25

    设计对83例早期卵巢癌样本进行基因表达分析,其中68例为I期癌变样本,15例为边界性病变样本。所有样本均为人类来源,采用微阵列技术检测总RNA表达,未涉及特定处理条件或分组混池方式,主要比较不同组织类型与疾病状态下的基因表达差异。

    摘要Gene expression was analysed in 68 stage I ovarian cancers and 15 borderline samples using microarrays. Tumors were obtained directly at surgery and immediately frozen in liquid nitrogen until analysis. Glass arrays containing 16000 genes were used. Data was interpreted by unsupervised and supervised analysis. All tumors had a wild-type p53. Unsupervised analysis identified eight major clusters one of which was statistically associated to overall survival, grading and histotype (cluster C) and another with grading and histotype (cluster D). Supervised analysis showed a clear association between histotypes and gene expression profile and distinguished the four major histotypes (serous, clear cells, mucinous, endometrioid). The data also discriminated between the different grades of the tumors. The subset of 15 borderline tumors were undistinguishable from grade 1 tumors. When patients, relapsing or not, were analysed, a subset of genes able to differentiate them was identified. The genes identified in the major clusters belong to general classes of lipid biosynthesis, transport and metabolism, immunoglobulins (antigen presenting and processing) and genes acting as metal, ion and anion transporters including ATPase activity coupled with ion transport. Keywords: disease state analysis

  6. 06 GSE8842 对83例卵巢肿瘤样本进行基因表达分析,其中68例来自早期卵巢癌患者,15例为边界性病变样本。样本为人类组织,采用微阵列技术检测总RNA表达,未涉及特定处理条件或分组处理,主要比较不同疾病状态下的基因表达特征。 人源 · 83 例 · GPL5689 · 2007/08/25

    设计对83例卵巢肿瘤样本进行基因表达分析,其中68例来自早期卵巢癌患者,15例为边界性病变样本。样本为人类组织,采用微阵列技术检测总RNA表达,未涉及特定处理条件或分组处理,主要比较不同疾病状态下的基因表达特征。

    摘要Gene expression was analysed in 68 stage I ovarian cancers and 15 borderline samples using microarrays. Tumors were obtained directly at surgery and immediately frozen in liquid nitrogen until analysis. Glass arrays containing 16000 genes were used. Data was interpreted by unsupervised and supervised analysis. All tumors had a wild-type p53. Unsupervised analysis identified eight major clusters one of which was statistically associated to overall survival, grading and histotype (cluster C) and another with grading and histotype (cluster D). Supervised analysis showed a clear association between histotypes and gene expression profile and distinguished the four major histotypes (serous, clear cells, mucinous, endometrioid). The data also discriminated between the different grades of the tumors. The subset of 15 borderline tumors were undistinguishable from grade 1 tumors. When patients, relapsing or not, were analysed, a subset of genes able to differentiate them was identified. The genes identified in the major clusters belong to general classes of lipid biosynthesis, transport and metabolism, immunoglobulins (antigen presenting and processing) and genes acting as metal, ion and anion transporters including ATPase activity coupled with ion transport. Keywords: disease state analysis

  7. 07 GSE318308 对卵巢癌复发患者的卵巢肿瘤组织进行RNA测序,比较durvalumab联合olaparib和cediranib(D+O+C)与durvalumab联合cediranib(D+C)两组的基因表达特征。研究包含39例D+O+C组患者(21例临床获益含4例例外反应者,10例无临床获益)及29例D+C组患者(14例临床获益含3例例外反应者,10例无临床获益),其中11例D+O+C组和9例D+C组患者提供配对预处理与治疗中样本。所有RNA样本经混池后使用NovaSeq Xplus 1.5B平台进行测序。 人源 · 75 例 · GPL34284 · 2026/02/06

    设计对卵巢癌复发患者的卵巢肿瘤组织进行RNA测序,比较durvalumab联合olaparib和cediranib(D+O+C)与durvalumab联合cediranib(D+C)两组的基因表达特征。研究包含39例D+O+C组患者(21例临床获益含4例例外反应者,10例无临床获益)及29例D+C组患者(14例临床获益含3例例外反应者,10例无临床获益),其中11例D+O+C组和9例D+C组患者提供配对预处理与治疗中样本。所有RNA样本经混池后使用NovaSeq Xplus 1.5B平台进行测序。

    摘要We report the efficacy and translational research findings of durvalumab, olaparib, and cediranib (D+O+C) and durvalumab plus cediranib (D+C) from the recurrent epithelial ovarian cancer (EOC) cohort within a single center, multi-arm, non-randomized, multi-cohort phase I/II trial (NCT02484404). Sixty-eight patients were enrolled (39 in D+O+C, 29 in D+C). The objective response rate (ORR) was 19.4% (95% CI, 9.5-43.5) for D+O+C and 29.6% (95% CI, 13.8-46.9) for D+C. Median progression-free survival (PFS) was 4.5 months in both arms, with each arm including four exceptional responders (PFS ≥ 12 months). Pre- and on-treatment biopsies and blood samples were collected for pre-specified transcriptomic and immunophenotypic profiling; signature analyses and preclinical studies were exploratory. We identified distinct transcriptional signatures associated with clinical outcomes. Baseline tumors from exceptional responders and patients with clinical benefit (partial response or stable disease [SD] with PFS ≥ 4 months) demonstrated strong enrichment of immune activation and metabolic pathways. Conversely, tumors with no clinical benefit (NCB; progressive disease or SD with PFS < 4 months) exhibited upregulation of vascular adaptation and cytoskeletal remodeling pathways. The correlation between immune, metabolic, and NCB signatures and clinical outcomes within each arm was independent of prior platinum response. These findings support proof-of-concept clinical activity of D+O+C and D+C and identify molecular signatures with potential predictive value in subsets of recurrent EOC.

  8. 08 GSE206422 对卵巢癌复发患者进行RNA-seq分析,比较接受BLBX、C4BX、EOTBX治疗与Primary组的肿瘤样本,以评估不同治疗方案对基因表达的影响。 人源 · 73 例 · GPL24676 · 2023/05/17

    设计对卵巢癌复发患者进行RNA-seq分析,比较接受BLBX、C4BX、EOTBX治疗与Primary组的肿瘤样本,以评估不同治疗方案对基因表达的影响。

    摘要Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase T cell infiltration into the tumor, and oral cyclophosphamide, to reduce the number of regulatory T cells. The trial accrued 40 heavily pretreated recurrent ovarian cancer patients. The primary endpoint, progression free survival, was extended to a median of 10.2 months. The secondary endpoints demonstrated an objective response rate of 47.5%, and disease control in 30% of patients for over a year while maintaining a good quality of life. We performed comprehensive molecular, immune, microbiome, and metabolic profiling on samples of trial patients. Here, we show increased T and B cell clusters and distinct microbial patterns with amino acid and lipid metabolism are linked to exceptional clinical responses. This study suggests the immune milieu and host-microbiome can be leveraged to improve antitumor response in future immunotherapy trials.

  9. 09 GSE319500 对高分级浆液性卵巢癌患者治疗前肿瘤活检样本与化疗后减瘤手术样本进行基因表达检测,采用NanoString nCounter Human PanCancer IO360 panel分析750个肿瘤微环境相关基因,比较治疗前后基因表达变化及不同化疗反应组(耐药、敏感、难治)的差异。 人源 · 70 例 · GPL27956 · 2026/02/17

    设计对高分级浆液性卵巢癌患者治疗前肿瘤活检样本与化疗后减瘤手术样本进行基因表达检测,采用NanoString nCounter Human PanCancer IO360 panel分析750个肿瘤微环境相关基因,比较治疗前后基因表达变化及不同化疗反应组(耐药、敏感、难治)的差异。

    摘要Given the interrelated mechanisms by which changes to the tumor microenvironment (TME) may drive disease recurrence, we test a novel machine learning approach to identifying key genes that may be involved in the likelihood of recurrence. The ability to compare pre- and post- NACT samples from the same patient shows how chemotherapy drives changes in the TME. We also had the opportunity to employ machine learning methods to investigate whether patient progression-free survival can be prediced from the impact of chemotherapy on the tumor microenvironment.

  10. 10 GSE230541 对铂类耐药复发卵巢癌的卵巢肿瘤组织进行RNA测序和全外显子组测序,检测转录组和基因组变异特征。 人源 · 60 例 · GPL16791 · 2023/05/01

    设计对铂类耐药复发卵巢癌的卵巢肿瘤组织进行RNA测序和全外显子组测序,检测转录组和基因组变异特征。

    摘要RNA sequencing and whole-exome sequencing data were obtained from 30 platinum-resistant recurrent ovarian cancer samples.

  11. 11 GSE44104 对60例卵巢癌患者的肿瘤组织进行全基因组表达分析,基于疾病阶段(III期)、复发状态(复发/非复发)及生存状态(生存/死亡)分组,通过微阵列分析比较不同组别间的基因表达差异,重点分析COL11A1的表达变化。 人源 · 60 例 · GPL570 · 2014/01/01

    设计对60例卵巢癌患者的肿瘤组织进行全基因组表达分析,基于疾病阶段(III期)、复发状态(复发/非复发)及生存状态(生存/死亡)分组,通过微阵列分析比较不同组别间的基因表达差异,重点分析COL11A1的表达变化。

    摘要Biomarkers that predict disease progression might assist the development of better therapeutic strategies for aggressive cancers, such as ovarian cancer. Here, we investigated the role of collagen type XI alpha 1 (COL11A1) in cell invasiveness and tumor formation and the prognostic impact of COL11A1 expression in ovarian cancer. Microarray analysis suggested that COL11A1 is a disease progression-associated gene that is linked to ovarian cancer recurrence and poor survival.

  12. 12 GSE240829 对28名III/IV期高分级浆液性卵巢癌患者的62个肿瘤样本(含31个原发肿瘤和31个复发肿瘤)进行RNA-Seq,其中11名患者携带致病性BRCA1/2突变。样本来源于卵巢组织、淋巴结、腹膜、阴道等部位,按肿瘤类型(原发/复发)和BRCA基因型(突变/未突变)分组,比较不同组别间的基因表达差异。 人源 · 57 例 · GPL11154 · 2023/08/19

    设计对28名III/IV期高分级浆液性卵巢癌患者的62个肿瘤样本(含31个原发肿瘤和31个复发肿瘤)进行RNA-Seq,其中11名患者携带致病性BRCA1/2突变。样本来源于卵巢组织、淋巴结、腹膜、阴道等部位,按肿瘤类型(原发/复发)和BRCA基因型(突变/未突变)分组,比较不同组别间的基因表达差异。

    摘要RNAseq was generated for a cohort of ovarian cancer patients to identify gene expression changes between primary and recurrent ovarian cancer tumors from patients with and without BRCA1/2 mutations

  13. 13 GSE295041 对24名患者匹配的原发性卵巢癌组织和复发性卵巢癌组织进行RNA测序,比较两组间转录组差异以识别复发相关遗传标志物。 人源 · 48 例 · GPL24676 · 2026/01/15

    设计对24名患者匹配的原发性卵巢癌组织和复发性卵巢癌组织进行RNA测序,比较两组间转录组差异以识别复发相关遗传标志物。

    摘要In this study, we performed a transcriptomic comparative analysis on formalin-fixed paraffin-embedded (FFPE) specimens, collecting both primary ovarian cancer tissue and recurrent ovarian cancer tissue in a series from the same patients in real-world settings. Our aim was to identify clinically significant Differentially Expressed Genes (DEGs) associated with the recurrence of HGSOC .

  14. 14 GSE55410 对复发且铂类耐药的上皮性卵巢癌患者,采集肿瘤和腹水活检样本,分别在治疗前和治疗后进行基因表达分析(Affymetrix Human 1.0ST芯片)和DNA甲基化分析(Illumina 27k Beadchip v1.2),比较治疗前后差异。 人源 · 26 例 · GPL6244 · 2014/03/04

    设计对复发且铂类耐药的上皮性卵巢癌患者,采集肿瘤和腹水活检样本,分别在治疗前和治疗后进行基因表达分析(Affymetrix Human 1.0ST芯片)和DNA甲基化分析(Illumina 27k Beadchip v1.2),比较治疗前后差异。

    摘要Gene expression (by Affymetrix GeneChip Human 1.0ST) profiling of biopsy samples from recurrent, platinum resistant epithelial ovarian cancer patients before and after treatment of decitabine in combination with carboplatin. The Illumina Infinium 27k Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 27,000 CpGs in PBMC (14 paired samples), tumor (8 paired samples) and ascites (6 paired samples) (GSE31826).

  15. 15 GSE214302 对铂金耐药(n=9)和敏感(n=10)的卵巢癌组织进行RNA-Seq分析,比较两组间的基因表达差异。研究对象为高分级浆液性卵巢癌患者术前肿瘤组织,分组依据铂金治疗反应状态,检测方式为RNA-Seq,主要比较耐药组与敏感组的表达谱。 人源 · 19 例 · GPL24676 · 2024/05/30

    设计对铂金耐药(n=9)和敏感(n=10)的卵巢癌组织进行RNA-Seq分析,比较两组间的基因表达差异。研究对象为高分级浆液性卵巢癌患者术前肿瘤组织,分组依据铂金治疗反应状态,检测方式为RNA-Seq,主要比较耐药组与敏感组的表达谱。

    摘要Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies. The most difficult issue in the treatment of ovarian cancer is the eventual development of platinum resistance. Accumulating studies have shown that circRNAs are abnormally aberrantly expressed in tumors and play critical roles in tumor growth, metastasis, stemness and resistance to therapy.To identify circRNAs that play crucial roles in maintaining the platinum resistance of ovarian cacner, we performed RNA-seq analysis in platinum-resistant(n=9) and -sensitive(n=10) ovarian cacner tissues. Candidate genes were identified by bioinformatic analysis and literature review.

微信二维码

课题合作 · 扫码加微信

bioinformaticsboy